LabTurbo Biotech Corporation
TTPEX:772523.00
TWD
0.00
(0.00%)
ISIN
TW0007725004
Return %
Stock
S&P 500
1Y
-9.80
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Chi Sheng Tai
- Full Time Employees
- 30
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 150, Chengde Rd. Taipei TP Taiwan 111
- IPO Date
- Dec 22, 2023
- Website
- labturbo.com.tw
- Similar Companies
- Business
- LabTurbo Biotech Corporation specializes in the research, development, manufacture, and sale of advanced molecular diagnostic systems and gene detection kits. Its core products include fully automated nucleic acid extraction instruments such as the LabTurbo AIO 48 SP-qPCR System, LabTurbo 48 Extraction System, LabTurbo QuadAIO System, and LabTurbo VacEZor Manual Extraction System. The company also provides a range of validated PCR diagnostic test kits for pathogens including respiratory infections, urinary tract infections (UTIs), sexually transmitted diseases (STDs), gastrointestinal infections, and pharmacogenomics (PGx). LabTurbo supports high-complexity laboratories with end-to-end automated solutions for DNA/RNA extraction, amplification, and detection, along with comprehensive clinical testing services designed for speed, accuracy, and scalability. LabTurbo operates primarily in Taiwan, the United States, and multiple other global markets including the Czech Republic, Spain, France, Israel, Singapore, the Philippines, and Malaysia. The company serves hospitals, clinical laboratories, and research institutions with a focus on infectious disease diagnostics and molecular testing. Founded in 2000 and headquartered in Taipei, Taiwan, LabTurbo has received recognition including the 2022 Outstanding Biotech Industry Award for advancing nucleic acid detection and epidemic support, and the National Innovation Award for its AIO 48 system's performance in COVID-19 detection. Recent developments include the launch of the LabTurbo Respiratory PCR Panel, a comprehensive test for detecting respiratory pathogens rapidly and accurately. The company has continued to expand its product offerings and scale operations to support the global demand for high-throughput and point-of-care molecular diagnostic solutions. LabTurbo maintains CAP certification and CLIA approval for its clinical testing laboratory operations, providing fast COVID-19 PCR testing with expedited services available within 6 to 24 hours. LabTurbo's portfolio and service expansion reflect strategic priorities to enhance sample-to-result automation, multiplex PCR testing capabilities, and workflow efficiencies for clinical diagnostics and scientific research markets worldwide. The company remains a key innovator in automated molecular diagnostic instruments and PCR diagnostic kits, driving improvements in laboratory efficiency and diagnostic precision. This description incorporates LabTurbo’s advanced instrument systems, validated diagnostic panels, recent product launches, industry awards, and its global operational footprint.